Algert Global LLC Sells 2,638 Shares of Medpace Holdings, Inc. $MEDP

Key Points

• Algert Global reduced its Medpace stake by 7.1%, selling 2,638 shares and retaining 34,477 shares valued at approximately $18.3 million. Institutional investors collectively own 77.98% of the company.
• Medpace insiders sold 125,661 shares worth about $73.9 million over the past 90 days, including sizable sales by a director and vice president; insiders still own 20.50% of the stock.
• Medpace exceeded quarterly expectations with adjusted EPS of $4.25 and revenue of $707.3 million, up 17.2% year over year. Despite strong results and a $620.03 share price, analysts maintain a consensus “Hold” rating with an average price target of $584.18.

Algert Global LLC reduced its stake in shares of Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 7.1% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 34,477 shares of the company's stock after selling 2,638 shares during the quarter. Algert Global LLC owned 0.12% of Medpace worth $18,259,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently made changes to their positions in MEDP. BOKF NA increased its holdings in shares of Medpace by 0.8% during the third quarter. BOKF NA now owns 2,542 shares of the company's stock worth $1,307,000 after buying an additional 20 shares in the last quarter. Valeo Financial Advisors LLC raised its stake in shares of Medpace by 5.0% in the fourth quarter. Valeo Financial Advisors LLC now owns 444 shares of the company's stock valued at $249,000 after acquiring an additional 21 shares during the last quarter. UMB Bank n.a. boosted its holdings in shares of Medpace by 5.6% in the 4th quarter. UMB Bank n.a. now owns 450 shares of the company's stock worth $253,000 after acquiring an additional 24 shares in the last quarter. Schulhoff & Co. Inc. boosted its holdings in shares of Medpace by 1.1% in the 4th quarter. Schulhoff & Co. Inc. now owns 2,202 shares of the company's stock worth $1,237,000 after acquiring an additional 25 shares in the last quarter. Finally, Balefire LLC grew its position in Medpace by 6.1% during the 1st quarter. Balefire LLC now owns 451 shares of the company's stock worth $217,000 after acquiring an additional 26 shares during the last quarter. 77.98% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other news, Director Brian T. Carley sold 5,000 shares of Medpace stock in a transaction that occurred on Wednesday, August 19th. The shares were sold at an average price of $608.63, for a total transaction of $3,043,150.00. Following the completion of the sale, the director owned 27,825 shares in the company, valued at $16,935,129.75. The trade was a 15.23% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, VP Susan E. Burwig sold 7,500 shares of the business's stock in a transaction that occurred on Tuesday, July 28th. The stock was sold at an average price of $600.00, for a total transaction of $4,500,000.00. Following the sale, the vice president directly owned 62,984 shares of the company's stock, valued at approximately $37,790,400. This trade represents a 10.64% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 125,661 shares of company stock valued at $73,854,945 over the last 90 days. Corporate insiders own 20.50% of the company's stock.

Medpace Price Performance

MEDP stock opened at $620.03 on Tuesday. The company has a 50 day moving average price of $553.21 and a 200 day moving average price of $492.40. Medpace Holdings, Inc. has a fifty-two week low of $373.00 and a fifty-two week high of $677.90. The stock has a market capitalization of $17.31 billion, a PE ratio of 36.34, a price-to-earnings-growth ratio of 2.77 and a beta of 1.15.

Medpace (NASDAQ:MEDP - Get Free Report) last announced its quarterly earnings data on Wednesday, July 22nd. The company reported $4.25 EPS for the quarter, beating analysts' consensus estimates of $3.98 by $0.27. The firm had revenue of $707.33 million for the quarter, compared to analyst estimates of $689.51 million. Medpace had a return on equity of 110.15% and a net margin of 17.67%.The business's quarterly revenue was up 17.2% compared to the same quarter last year. During the same period last year, the company earned $3.10 EPS. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. As a group, equities analysts expect that Medpace Holdings, Inc. will post 17.54 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

MEDP has been the subject of a number of recent analyst reports. Jefferies Financial Group cut Medpace from a "buy" rating to a "hold" rating and raised their price target for the company from $490.00 to $515.00 in a report on Tuesday, July 7th. Deutsche Bank Aktiengesellschaft restated a "hold" rating and set a $535.00 target price on shares of Medpace in a report on Thursday, July 23rd. Leerink Partners set a $620.00 target price on Medpace in a research note on Thursday, July 23rd. Royal Bank Of Canada lifted their price target on Medpace from $484.00 to $692.00 and gave the company an "outperform" rating in a report on Friday, July 24th. Finally, Robert W. Baird upped their price target on shares of Medpace from $547.00 to $624.00 and gave the stock a "neutral" rating in a research report on Friday, July 24th. Three equities research analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the company's stock. Based on data from MarketBeat.com, the company currently has an average rating of "Hold" and a consensus target price of $584.18.

About Medpace

Medpace Holdings, Inc NASDAQ: MEDP is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace's core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.

Want to see what other hedge funds are holding MEDP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source